Alembic Pharmaceuticals has announced the opening of a special window for shareholders to transfer and dematerialise their physical securities. The pharmaceutical company issued newspaper advertisements on 15th April, 2026, informing stakeholders about this important corporate development.

Special Window Details

The special window operates under SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated 30th January, 2026. This initiative provides shareholders with an opportunity to convert their physical securities to dematerialised form.

Eligibility and Process

The special window covers securities that were sold or purchased before 1st April, 2019. Additionally, it accommodates transfer requests that were previously submitted but rejected, returned, or not processed due to document deficiencies or procedural issues.

Eligible investors must submit their transfer requests along with requisite documents to the company's Registrar and Transfer Agent. The securities transferred during this window period will be credited in demat form and will remain under lock-in for one year from the date of registration of transfer.

Registrar and Transfer Agent Information

Shareholders need to contact MUFG Intime India Private Limited for processing their requests. The RTA operates as the designated unit for Alembic Pharmaceuticals Limited.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The newspaper advertisements were published in Indian Express (English Edition) and Financial Express (Gujarati Edition) on 15th April, 2026.

Company Secretary Mahisha Saraf signed the regulatory communication to both BSE Limited and National Stock Exchange of India Ltd, ensuring compliance with stock exchange requirements. The company maintains its registered office at Alembic Road, Vadodara - 390 003.

Alembic Pharmaceuticals Limited has filed its quarterly compliance certificate with stock exchanges, fulfilling mandatory regulatory requirements under SEBI regulations. The pharmaceutical company submitted the certificate on 8th April, 2026, covering the quarter ended 31st March, 2026.

Regulatory Compliance Filing

The company filed a Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 with both BSE and NSE. Company Secretary Manisha Saraf signed the filing, which was submitted to ensure compliance with securities market regulations.

Registrar Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serves as the registrar and share transfer agent for Alembic Pharmaceuticals. The registrar issued the compliance certificate on April 3, 2026, confirming proper handling of securities dematerialisation processes.

Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India, signed the certificate confirming that:

• Securities received from depository participants for dematerialisation during the quarter were properly confirmed
• Security certificates received were mutilated and cancelled after due verification
• Depository names were substituted in the register of members within prescribed timelines
• All securities are listed on stock exchanges where earlier issued securities are listed

Stock Exchange Details

The filing was submitted to both major Indian stock exchanges where Alembic Pharmaceuticals shares are traded.

This routine compliance filing demonstrates the company's adherence to SEBI regulations governing depositories and participants, ensuring transparent and proper handling of shareholder securities during the dematerialisation process.